Literature DB >> 8519644

Is mucinous carcinoma of the colorectum a distinct genetic entity?

C Hanski1.   

Abstract

Mucinous carcinomas are defined on the basis of the amount of the mucus component in the tumour mass. Apart from this quantitative criterion, a number of clinicopathological parameters (such as localisation, prevalence in different countries and age groups, association with HNPCC and inflammatory processes) and genetic alterations (e.g. frequency of mutation in Ki-ras and p53 genes, level of MUC2 expression) differentiate these tumours from the non-mucinous ones. Since a different set of genetic lesions implies different inducing agents, these observations suggest that there may be a 'mucinous pathway of carcinogenesis'. Further identification of genetic changes characteristic of the mucinous phenotype will help to understand the aetiology of these tumours and possibly establish markers for detection of the high-risk group.

Entities:  

Mesh:

Year:  1995        PMID: 8519644      PMCID: PMC2034069          DOI: 10.1038/bjc.1995.514

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  108 in total

1.  Colorectal carcinoma in patients with Crohn's disease.

Authors:  S R Hamilton
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

2.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

3.  Mucinous colon carcinoma in a black family.

Authors:  D T Purtilo; G W Geelhoed; F P Li; J P Yang; W A Thurber; J Darrah; C Cassel
Journal:  Cancer Genet Cytogenet       Date:  1987-01

4.  Histopathology of colorectal carcinomas and adenomas in cancer family syndrome.

Authors:  J P Mecklin; P Sipponen; H J Järvinen
Journal:  Dis Colon Rectum       Date:  1986-12       Impact factor: 4.585

5.  Mucoid colonic carcinoma as an autosomal-dominant inherited syndrome.

Authors:  D C Budd; D L Fink
Journal:  Arch Surg       Date:  1981-07

6.  Mucinous carcinomas of the colon and rectum and their relation to polyps.

Authors:  A S Sundblad; R A Paz
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

7.  Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene.

Authors:  M D Erisman; P G Rothberg; R E Diehl; C C Morse; J M Spandorfer; S M Astrin
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

8.  The natural history of colorectal carcinoma in adolescents.

Authors:  V Odone; L Chang; J Caces; S L George; C B Pratt
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

9.  Peculiarities of mucinous colorectal carcinoma.

Authors:  H C Umpleby; D L Ranson; R C Williamson
Journal:  Br J Surg       Date:  1985-09       Impact factor: 6.939

10.  Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma.

Authors:  P G Rothberg; J M Spandorfer; M D Erisman; R N Staroscik; H F Sears; R O Petersen; S M Astrin
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

View more
  14 in total

1.  Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups.

Authors:  J M Chiang; C Y Yeh; C R Changchien; J S Chen; R Tang; J R Chen
Journal:  Int J Colorectal Dis       Date:  2010-06-08       Impact factor: 2.571

2.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

Review 3.  Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.

Authors:  Thomas Winder; Heinz-Josef Lenz
Journal:  Oncologist       Date:  2010-07-23

4.  Identification of a lower grade muconodular subtype of gastric mucinous cancer.

Authors:  Enrico Solcia; Ombretta Luinetti; Francesca Tava; Catherine Klersy; Federica Grillo; Nicola Pandolfo; Roberto Fiocca
Journal:  Virchows Arch       Date:  2004-10-28       Impact factor: 4.064

5.  Prognostic implications of mucinous histology in stage III colon cancer with the receipt of adjuvant chemotherapy.

Authors:  Feng Yu; Luqiao Huang; Feng Shen; Shuang Wu; Jian Chen
Journal:  J Gastrointest Oncol       Date:  2020-10

Review 6.  Mucinous carcinoma of the rectum: a distinct clinicopathological entity.

Authors:  M Chand; S Yu; R I Swift; G Brown
Journal:  Tech Coloproctol       Date:  2013-12-11       Impact factor: 3.781

Review 7.  Advances in the care of patients with mucinous colorectal cancer.

Authors:  Niek Hugen; Gina Brown; Robert Glynne-Jones; Johannes H W de Wilt; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

8.  Predicting Treatment Response to Neoadjuvant Chemoradiotherapy in Rectal Mucinous Adenocarcinoma Using an MRI-Based Radiomics Nomogram.

Authors:  Zhihui Li; Shuai Li; Shuqin Zang; Xiaolu Ma; Fangying Chen; Yuwei Xia; Liuping Chen; Fu Shen; Yong Lu; Jianping Lu
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

9.  The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease.

Authors:  Masakatsu Numata; Manabu Shiozawa; Takuo Watanabe; Hiroshi Tamagawa; Naoto Yamamoto; Soichiro Morinaga; Kazuteru Watanabe; Teni Godai; Takashi Oshima; Shoichi Fujii; Chikara Kunisaki; Yasushi Rino; Munetaka Masuda; Makoto Akaike
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

10.  Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

Authors:  V Catalano; F Loupakis; F Graziano; U Torresi; R Bisonni; D Mari; L Fornaro; A M Baldelli; P Giordani; D Rossi; P Alessandroni; L Giustini; R R Silva; A Falcone; S D'Emidio; S L Fedeli
Journal:  Br J Cancer       Date:  2009-03-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.